1. Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am J Clin Dermatol. 2020;21(6):783–98.
2. He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–92.
3. Agency MHPR. Abrocitinib (CIBINQO®): 50mg film-coated tablets: summary of product characteristics. 2021. https://mhraproducts4853.blob.core.windows.net/docs/3b68809595392199c87a314cd40e80146a1fa36b. Accessed 13 Sept 2021.
4. Agency MHPR. Abrocitinib (CIBINQO®): 100mg film-coated tablets: summary of product characteristics. 2021. https://mhraproducts4853.blob.core.windows.net/docs/cec4db859df0798598d52dd5da18f77adb972e29. Accessed 13 Sept 2021.
5. Agency MHPR. Abrocitinib (CIBINQO®): 200mg film-coated tablets: summary of product characteristics. 2021. https://mhraproducts4853.blob.core.windows.net/docs/9106b0ca62531780c94245a0eb6894ba3a43a8bf. Accessed 13 Sept 2021.